|
Post by sayhey24 on Oct 29, 2018 18:46:07 GMT -5
☰ Receptor Life Sciences raises $29M, unveils its work on inhaler for medicines based on cannabis By Clare McGrane on October 29, 2018 at 1:43 pm Receptor Life Sciences CEO Gregory Wesner. (Lane Powell Photo) Seattle-based biotech company Receptor Life Sciences announced a $29 million series A funding round Monday as it emerged from stealth mode, unveiling its work on medicines derived from cannabis. The $29 million is the first time the company has raised funds. Through a spokesperson, it declined to identify its investors.Arthur Rubinfeld, a longtime executive at Starbucks, is listed as a director of the company in an SEC filing that disclosed the new funding. Rubinfeld left Starbucks, where he was most recently the president of global innovation at the company’s roastery, in 2016. He is also the founder of Airvision, an advisory firm specializing in consumer oriented businesses. Is that a mistake, or does this mean that the previous raise was included in this one? Or are they the same raise, and the value just increased? mnkd.proboards.com/thread/10535/raises-therapies-based-plant-extracts"Secretive biotechnology company Receptor Life Sciences has raised a funding round totaling just over $7.5 million, according to a filing with the Securities and Exchange Commission." I think you have two companies Receptor Holdings and Receptor Life. Life raised 7.5 and Holdings raise $21.5.
Receptor Holdings, Inc. and its wholly-owned subsidiary, Receptor Life Sciences, a biopharmaceutical company developing cannabinoid medicines featuring distinct pharmaceutical drug delivery technologies, today announced that it raised $29 million in a combined convertible debt and Series A round of financing.
|
|
|
Post by goyocafe on Oct 29, 2018 18:47:31 GMT -5
Is that a mistake, or does this mean that the previous raise was included in this one? Or are they the same raise, and the value just increased? mnkd.proboards.com/thread/10535/raises-therapies-based-plant-extracts"Secretive biotechnology company Receptor Life Sciences has raised a funding round totaling just over $7.5 million, according to a filing with the Securities and Exchange Commission." I think you have two companies Receptor Holdings and Receptor Life. Life raised 7.5 and Holdings raise $21.5.
Receptor Holdings, Inc. and its wholly-owned subsidiary, Receptor Life Sciences, a biopharmaceutical company developing cannabinoid medicines featuring distinct pharmaceutical drug delivery technologies, today announced that it raised $29 million in a combined convertible debt and Series A round of financing.
I sure hope that debt doesn't include Deerfield.
|
|
|
Post by sportsrancho on Oct 29, 2018 18:49:07 GMT -5
|
|
|
Post by peppy on Oct 29, 2018 18:51:50 GMT -5
Can we post thing thing we could not post before for copyright? I have a copy.
|
|
|
Post by tinkusr8215 on Oct 29, 2018 18:52:10 GMT -5
finally.
|
|
|
Post by sportsrancho on Oct 29, 2018 18:52:36 GMT -5
|
|
|
Post by cretin11 on Oct 29, 2018 18:53:42 GMT -5
Hmm, what does that mean? Fortnight like the game?
|
|
|
Post by sayhey24 on Oct 29, 2018 18:54:32 GMT -5
I think you have two companies Receptor Holdings and Receptor Life. Life raised 7.5 and Holdings raise $21.5.
Receptor Holdings, Inc. and its wholly-owned subsidiary, Receptor Life Sciences, a biopharmaceutical company developing cannabinoid medicines featuring distinct pharmaceutical drug delivery technologies, today announced that it raised $29 million in a combined convertible debt and Series A round of financing.
I sure hope that debt doesn't include Deerfield. I think Kevin Johnson has more money than Deerfield.
|
|
|
Post by figglebird on Oct 29, 2018 18:55:13 GMT -5
It probably does BUT what is unclear is mnkd's(ownership) stake if any beyond the straight liscensing deal - which may prove complicated based on today's wording. Several things here seem to be in opposition - NONE OF WHICH IS NEGATIVE - but here is what I know.
1. about 7 weeks ago matt defined the relationship to rls as such(lic partner/non venture) - so unless this has changed, why is RLS basically advertising the same line of business that is mannkind's.
2. there is no mention in the pr of joint or subsidiary only that they chose the ONLY VIABLE pulmonary platfiorm in existence to develop product(tscannaboid)
---
MANY POSSIBILITIES
|
|
|
Post by n8 on Oct 29, 2018 18:56:37 GMT -5
Something definite in the next two weeks?
|
|
|
Post by peppy on Oct 29, 2018 19:01:17 GMT -5
It probably does BUT what is unclear is mnkd's(ownership) stake if any beyond the straight liscensing deal - which may prove complicated based on today's wording. Several things here seem to be in opposition - NONE OF WHICH IS NEGATIVE - but here is what I know. 1. about 7 weeks ago matt defined the relationship to rls as such(lic partner/non venture) - so unless this has changed, why is RLS basically advertising the same line of business that is mannkind's. 2. there is no mention in the pr of joint or subsidiary only that they chose the ONLY VIABLE pulmonary platfiorm in existence to develop product(tscannaboid)--- MANY POSSIBILITIES www.receptorlife.com
|
|
|
Post by goyocafe on Oct 29, 2018 19:03:07 GMT -5
So who is Receptor Holdings, Inc, and who is Receptor Life Sciences? I think Receptor Life Sciences is noted on the website.
|
|
|
Post by mytakeonit on Oct 29, 2018 19:21:45 GMT -5
Receptor Holdings, Inc. and its wholly-owned subsidiary, Receptor Life Sciences
Password for understanding it is ... "Maui Wowie"
|
|
|
Post by sportsrancho on Oct 29, 2018 19:45:24 GMT -5
|
|
|
Post by mnholdem on Oct 29, 2018 20:26:44 GMT -5
"Receptor Holdings also plans to introduce its disruptive technologies to the non-prescription cannabinoid markets that are developing in Canada, Europe and elsewhere." OTC = royalty revenue much sooner than with NDA process... we need $ now I would think that the FDA would be very supportive of precision delivery.
|
|